NS, J., YT, T., KC, A., & S, L. (2021). Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press.
Chicago Style (17th ed.) CitationNS, Joseph, Tai YT, Anderson KC, and Lonial S. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press, 2021.
MLA (8th ed.) CitationNS, Joseph, et al. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.